Tirzepatide timeline: what the published trials and research reports show
Tirzepatide pairs a GLP-1 and a GIP receptor action in one molecule, and its published trial data is some of the most complete in this category. As with any GLP-1 class compound, tolerability and the trial's weight results are two separate questions worth answering separately.
What the published trial reported
| Trial | SURMOUNT-1 (NEJM, 2022) |
| Population | Adults with obesity or overweight, no diabetes |
| Dose | 5, 10 or 15 mg once weekly, titrated from 2.5 mg |
| Duration | 72 weeks |
| Result | Mean weight change of roughly 15%, 19% and 21% at the 5, 10 and 15 mg doses |
This is trial-level data under medical supervision, on pharmaceutical-grade product with a structured titration. It describes what the trial measured, not a personal outcome to expect from research use.
Weeks 1 to 4: tolerability dose
The trial opens at 2.5 mg weekly, a dose picked for tolerability rather than effect. Reports at this stage commonly describe mild nausea or appetite change, generally milder than at later dose steps.
Weeks 5 to 20: stepping toward maintenance
The dose rises by 2.5 mg every four weeks toward whichever maintenance level is being studied. GI effects, nausea, diarrhea and constipation, were the most commonly reported issue in the trial and in wider reporting, concentrated around each increase rather than spread evenly.
Weeks 20 to 72: the trial's measured result
Weight change in the trial continued building well past the point where the dose held steady, with no plateau observed through the full 72 weeks at the higher doses. Slower titration was specifically associated with fewer GI complaints, the closest thing to a controlled comparison on that question.
Common questions
Does a faster titration change the trial outcome? The trial's slower steps were associated with less nausea, not a different endpoint, so the titration speed is mainly a tolerability lever rather than an efficacy one.
How does this compare to retatrutide? Retatrutide adds a third receptor, glucagon, on top of tirzepatide's two. See the retatrutide vs tirzepatide comparison for the trial-level detail.
For the full mechanism, titration schedule and citations, see the tirzepatide reference page.